Previous close | 3.1280 |
Open | 3.1280 |
Bid | 3.1360 x 33800 |
Ask | 3.2040 x 33100 |
Day's range | 3.1280 - 3.1280 |
52-week range | 0.9770 - 7.0950 |
Volume | |
Avg. volume | 1 |
Market cap | 199.071M |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.6700 |
Earnings date | 01 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.63 |
SEATTLE, March 27, 2024--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
SEATTLE, February 20, 2024--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
SEATTLE, February 01, 2024--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP ("DRI"), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.